CHEMOTHERAPY-INDUCED NEUTROPENIA IN HIV POSITIVE PATIENTS WITH LYMPHOMA: COMPARISON OF PEGFILGRASTIM WITH DAILY FILGRASTIM ADMINISTRATION.
Abstract
We retrospectively compared the incidence of neutropenia in two groups of HIV patients with lymphoma, who underwent chemotherapy supported by once-per-cycle administration of pegfilgrastim or by daily subcutaneous injection of filgrastim, respectively. Our findings indicate that pegfilgrastim and filgastrim produce similar results in preventing both neutropenia and febrile neutropenia.
Keywords
References
Vaccher E, Spina M, Talamini R, Zanetti M, di Gennaro G, Nasti G,et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy (2003) Clin Infect Dis 37: 1556-64.
Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood 2012; 119:3245-55.
Michieli M, Mazzucato M, Tirelli U, De Paoli P. Stem cell transplantation for
lymphoma patients with HIV infection. Cell Transplant. 2011; 20:351-70.
Lyman GH. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action (2005). Expert Opin Biol Ther 5:1635-46. Review.
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8-32.
Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011; 11:404.
Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U. (2003) Therapeutic approaches to AIDS-related malignancies. Oncogene 22: 6646-59.
Hartmann P, Rehwald U, Salzberger B, Franzen C, Sieber M, Wohrmann A, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection . Ann Oncol 2003; 14: 1562-9.
Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002; 13: 1264-74.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-205.
Anderlini P, Champlin R. Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy. Drugs. 2002;62 Suppl 1:79-88.
Kobbe G, Bruns I, Fenk R, Czibere A, Haas R. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant. 2009;43:669-77.
Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14: 133-40.
Pluda JM, Mitsuya H, Yarchoan R. Hematologic effects of AIDS therapies. Hematol Oncol Clin North Am 1991; 5: 229-48.
Cingolani A, Torti L, Pinnetti C, de Gaetano Donati K, Murri R, Tacconelli E, Larocca LM, Teofili L. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's
lymphoma. AIDS. 2010; 24: 2408-12
Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 2006; 47: 1822-9.
Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, Wollins DS American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30:1715-24.
Refbacks
- There are currently no refbacks.
Mediterr J Hematol Infect Dis ISSN 2035-3006